{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T01:59:24Z","timestamp":1792634364674,"version":"4.5.0"},"reference-count":177,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,5,17]],"date-time":"2023-05-17T00:00:00Z","timestamp":1684281600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,5,17]],"date-time":"2023-05-17T00:00:00Z","timestamp":1684281600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Calcif Tissue Int"],"DOI":"10.1007\/s00223-023-01093-0","type":"journal-article","created":{"date-parts":[[2023,5,17]],"date-time":"2023-05-17T03:27:22Z","timestamp":1684294042000},"page":"21-38","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":37,"title":["Metabolic Health and Disease: A Role of Osteokines?"],"prefix":"10.1007","volume":"113","author":[{"given":"Anika","family":"Shimonty","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lynda F.","family":"Bonewald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8632-5791","authenticated-orcid":false,"given":"Joshua R.","family":"Huot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,5,17]]},"reference":[{"key":"1093_CR1","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1089\/met.2018.0105","volume":"17","author":"J Araujo","year":"2019","unstructured":"Araujo J, Cai J, Stevens J (2019) Prevalence of optimal metabolic health in American adults: National health and nutrition examination survey 2009\u20132016. Metab Syndr Relat Disord 17:46\u201352","journal-title":"Metab Syndr Relat Disord"},{"key":"1093_CR2","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.amepre.2021.12.021","volume":"63","author":"A Rafei","year":"2022","unstructured":"Rafei A, Elliott MR, Jones RE, Riosmena F, Cunningham SA, Mehta NK (2022) Obesity incidence in U.S. children and young adults: a pooled analysis. Am J Prev Med 63:51\u201359","journal-title":"Am J Prev Med"},{"key":"1093_CR3","doi-asserted-by":"publisher","first-page":"109924","DOI":"10.1016\/j.diabres.2022.109924","volume":"188","author":"JJ Noubiap","year":"2022","unstructured":"Noubiap JJ, Nansseu JR, Lontchi-Yimagou E, Nkeck JR, Nyaga UF, Ngouo AT, Tounouga DN, Tianyi FL, Foka AJ, Ndoadoumgue AL, Bigna JJ (2022) Geographic distribution of metabolic syndrome and its components in the general adult population: a meta-analysis of global data from 28 million individuals. Diabetes Res Clin Pract 188:109924","journal-title":"Diabetes Res Clin Pract"},{"key":"1093_CR4","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1002\/hep.28431","volume":"64","author":"ZM Younossi","year":"2016","unstructured":"Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M (2016) Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology 64:73\u201384","journal-title":"Hepatology"},{"key":"1093_CR5","volume-title":"Physiology, liver","author":"A Kalra","year":"2022","unstructured":"Kalra A, Yetiskul E, Wehrle CJ, Tuma F (2022) Physiology, liver. StatPearls, Treasure Island"},{"key":"1093_CR6","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1016\/j.jamda.2016.04.019","volume":"17","author":"JM Argiles","year":"2016","unstructured":"Argiles JM, Campos N, Lopez-Pedrosa JM, Rueda R, Rodriguez-Manas L (2016) Skeletal muscle regulates metabolism via interorgan crosstalk: roles in health and disease. J Am Med Dir Assoc 17:789\u2013796","journal-title":"J Am Med Dir Assoc"},{"key":"1093_CR7","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.bbacli.2016.03.002","volume":"5","author":"TW Jung","year":"2016","unstructured":"Jung TW, Yoo HJ, Choi KM (2016) Implication of hepatokines in metabolic disorders and cardiovascular diseases. BBA Clin 5:108\u2013113","journal-title":"BBA Clin"},{"key":"1093_CR8","doi-asserted-by":"publisher","first-page":"143","DOI":"10.2478\/jtim-2019-0029","volume":"7","author":"Y Ke","year":"2019","unstructured":"Ke Y, Xu C, Lin J, Li Y (2019) Role of hepatokines in non-alcoholic fatty liver disease. J Transl Int Med 7:143\u2013148","journal-title":"J Transl Int Med"},{"key":"1093_CR9","doi-asserted-by":"publisher","first-page":"2118","DOI":"10.1177\/15353702211009213","volume":"246","author":"F Pin","year":"2021","unstructured":"Pin F, Bonewald LF, Bonetto A (2021) Role of myokines and osteokines in cancer cachexia. Exp Biol Med (Maywood) 246:2118\u20132127","journal-title":"Exp Biol Med (Maywood)"},{"key":"1093_CR10","volume-title":"Endotext","author":"S Zaheer","year":"2000","unstructured":"Zaheer S, LeBoff MS (2000) Osteoporosis: prevention and treatment. In: Feingold KR, Anawalt B, Blackman MR, Boyce A, Chrousos G, Corpas E, de Herder WW, Dhatariya K, Hofland J, Dungan K, Hofland J, Kalra S, Kaltsas G, Kapoor N, Koch C, Kopp P, Korbonits M, Kovacs CS, Kuohung W, Laferrere B, Levy M, McGee EA, McLachlan R, New M, Purnell J, Sahay R, Singer F, Sperling MA, Stratakis CA, Trence DL, Wilson DP (eds) Endotext. MDText.com. Inc., South Dartmouth"},{"key":"1093_CR11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.15620\/cdc:103477","volume-title":"Osteoporosis or low bone mass in older adults: United States, 2017\u20132018","author":"N Sarafrazi","year":"2021","unstructured":"Sarafrazi N, Wambogo EA, Shepherd JA (2021) Osteoporosis or low bone mass in older adults: United States, 2017\u20132018. NCHS Data Brief, pp 1\u20138"},{"key":"1093_CR12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12902-022-01260-8","volume":"23","author":"X Liu","year":"2023","unstructured":"Liu X, Chen F, Liu L, Zhang Q (2023) Prevalence of osteoporosis in patients with diabetes mellitus: a systematic review and meta-analysis of observational studies. BMC Endocr Disord 23:1","journal-title":"BMC Endocr Disord"},{"key":"1093_CR13","doi-asserted-by":"publisher","first-page":"1052592","DOI":"10.3389\/fendo.2022.1052592","volume":"13","author":"B Wu","year":"2022","unstructured":"Wu B, Fu Z, Wang X, Zhou P, Yang Q, Jiang Y, Zhu D (2022) A narrative review of diabetic bone disease: characteristics, pathogenesis, and treatment. Front Endocrinol (Lausanne) 13:1052592","journal-title":"Front Endocrinol (Lausanne)"},{"key":"1093_CR14","doi-asserted-by":"publisher","first-page":"2275","DOI":"10.1007\/s00198-022-06459-y","volume":"33","author":"B Pan","year":"2022","unstructured":"Pan B, Cai J, Zhao P, Liu J, Fu S, Jing G, Niu Q, Li Q (2022) Relationship between prevalence and risk of osteoporosis or osteoporotic fracture with non-alcoholic fatty liver disease: a systematic review and meta-analysis. Osteoporos Int 33:2275\u20132286","journal-title":"Osteoporos Int"},{"key":"1093_CR15","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1007\/s00198-023-06687-w","volume":"34","author":"J Liu","year":"2023","unstructured":"Liu J, Tang Y, Feng Z, Chen Y, Zhang X, Xia Y, Geng B (2023) Metabolic associated fatty liver disease and bone mineral density: a cross-sectional study of the National health and nutrition examination survey 2017\u20132018. Osteoporos Int 34:713","journal-title":"Osteoporos Int"},{"key":"1093_CR16","first-page":"e33721","volume":"15","author":"J Kang","year":"2023","unstructured":"Kang J, Gopakumar H, Puli SR (2023) Prevalence of osteoporosis in cirrhosis: a systematic review and meta-analysis. Cureus 15:e33721","journal-title":"Cureus"},{"key":"1093_CR17","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1016\/S1470-2045(10)70218-7","volume":"12","author":"K Fearon","year":"2011","unstructured":"Fearon K, Strasser F, Anker SD, Bosaeus I, Bruera E, Fainsinger RL, Jatoi A, Loprinzi C, MacDonald N, Mantovani G, Davis M, Muscaritoli M, Ottery F, Radbruch L, Ravasco P, Walsh D, Wilcock A, Kaasa S, Baracos VE (2011) Definition and classification of cancer cachexia: an international consensus. Lancet Oncol 12:489\u2013495","journal-title":"Lancet Oncol"},{"key":"1093_CR18","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1093\/jjco\/hyf082","volume":"32","author":"YC Hung","year":"2002","unstructured":"Hung YC, Yeh LS, Chang WC, Lin CC, Kao CH (2002) Prospective study of decreased bone mineral density in patients with cervical cancer without bone metastases: a preliminary report. Jpn J Clin Oncol 32:422\u2013424","journal-title":"Jpn J Clin Oncol"},{"key":"1093_CR19","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1038\/sj.bjc.6690188","volume":"79","author":"JA Kanis","year":"1999","unstructured":"Kanis JA, McCloskey EV, Powles T, Paterson AH, Ashley S, Spector T (1999) A high incidence of vertebral fracture in women with breast cancer. Br J Cancer 79:1179\u20131181","journal-title":"Br J Cancer"},{"key":"1093_CR20","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1007\/s00198-022-06631-4","volume":"34","author":"C Ye","year":"2023","unstructured":"Ye C, Leslie WD (2023) Fracture risk and assessment in adults with cancer. Osteoporos Int 34:449\u2013466","journal-title":"Osteoporos Int"},{"key":"1093_CR21","doi-asserted-by":"publisher","first-page":"40","DOI":"10.21037\/atm-20-4708","volume":"9","author":"D Wu","year":"2021","unstructured":"Wu D, Wu XD, Zhou X, Huang W, Luo C, Liu Y (2021) Bone mineral density, osteopenia, osteoporosis, and fracture risk in patients with atopic dermatitis: a systematic review and meta-analysis. Ann Transl Med 9:40","journal-title":"Ann Transl Med"},{"key":"1093_CR22","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1016\/j.bone.2015.02.016","volume":"75","author":"PR Buenzli","year":"2015","unstructured":"Buenzli PR, Sims NA (2015) Quantifying the osteocyte network in the human skeleton. Bone 75:144\u2013150","journal-title":"Bone"},{"key":"1093_CR23","doi-asserted-by":"publisher","first-page":"e0138189","DOI":"10.1371\/journal.pone.0138189","volume":"10","author":"J Xiong","year":"2015","unstructured":"Xiong J, Piemontese M, Onal M, Campbell J, Goellner JJ, Dusevich V, Bonewald L, Manolagas SC, O\u2019Brien CA (2015) Osteocytes, not osteoblasts or lining cells, are the main source of the RANKL required for osteoclast formation in remodeling bone. PLoS ONE 10:e0138189","journal-title":"PLoS ONE"},{"key":"1093_CR24","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1002\/jbmr.1547","volume":"27","author":"J Xiong","year":"2012","unstructured":"Xiong J, O\u2019Brien CA (2012) Osteocyte RANKL: new insights into the control of bone remodeling. J Bone Miner Res 27:499\u2013505","journal-title":"J Bone Miner Res"},{"key":"1093_CR25","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/s41232-019-0111-3","volume":"40","author":"T Ono","year":"2020","unstructured":"Ono T, Hayashi M, Sasaki F, Nakashima T (2020) RANKL biology: bone metabolism, the immune system, and beyond. Inflamm Regen 40:2","journal-title":"Inflamm Regen"},{"key":"1093_CR26","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1111\/clr.14010","volume":"33","author":"X Lv","year":"2022","unstructured":"Lv X, Zou L, Zhang X, Zhang X, Lai H, Shi J (2022) Effects of diabetes\/hyperglycemia on peri-implant biomarkers and clinical and radiographic outcomes in patients with dental implant restorations: a systematic review and meta-analysis. Clin Oral Implants Res 33:1183\u20131198","journal-title":"Clin Oral Implants Res"},{"key":"1093_CR27","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1038\/nm.3084","volume":"19","author":"S Kiechl","year":"2013","unstructured":"Kiechl S, Wittmann J, Giaccari A, Knoflach M, Willeit P, Bozec A, Moschen AR, Muscogiuri G, Sorice GP, Kireva T, Summerer M, Wirtz S, Luther J, Mielenz D, Billmeier U, Egger G, Mayr A, Oberhollenzer F, Kronenberg F, Orthofer M, Penninger JM, Meigs JB, Bonora E, Tilg H, Willeit J, Schett G (2013) Blockade of receptor activator of nuclear factor-kappaB (RANKL) signaling improves hepatic insulin resistance and prevents development of diabetes mellitus. Nat Med 19:358\u2013363","journal-title":"Nat Med"},{"key":"1093_CR28","doi-asserted-by":"publisher","first-page":"2049","DOI":"10.1016\/j.jacc.2010.03.013","volume":"55","author":"SM Venuraju","year":"2010","unstructured":"Venuraju SM, Yerramasu A, Corder R, Lahiri A (2010) Osteoprotegerin as a predictor of coronary artery disease and cardiovascular mortality and morbidity. J Am Coll Cardiol 55:2049\u20132061","journal-title":"J Am Coll Cardiol"},{"key":"1093_CR29","doi-asserted-by":"publisher","first-page":"20","DOI":"10.3390\/jcm12020451","volume":"12","author":"N Lu","year":"2023","unstructured":"Lu N, Shan C, Fu JR, Zhang Y, Wang YY, Zhu YC, Yu J, Cai J, Li SX, Tao T, Liu W (2023) RANKL is independently associated with increased risks of non-alcoholic fatty liver disease in Chinese women with PCOS: a cross-sectional study. J Clin Med 12:20","journal-title":"J Clin Med"},{"key":"1093_CR30","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1016\/j.jhep.2005.05.034","volume":"43","author":"AR Moschen","year":"2005","unstructured":"Moschen AR, Kaser A, Stadlmann S, Millonig G, Kaser S, Muhllechner P, Habior A, Graziadei I, Vogel W, Tilg H (2005) The RANKL\/OPG system and bone mineral density in patients with chronic liver disease. J Hepatol 43:973\u2013983","journal-title":"J Hepatol"},{"key":"1093_CR31","doi-asserted-by":"publisher","first-page":"3811","DOI":"10.18632\/oncotarget.14013","volume":"8","author":"S Kiechl","year":"2017","unstructured":"Kiechl S, Schramek D, Widschwendter M, Fourkala EO, Zaikin A, Jones A, Jaeger B, Rack B, Janni W, Scholz C, Willeit J, Weger S, Mayr A, Teschendorff A, Rosenthal A, Fraser L, Philpott S, Dubeau L, Keshtgar M, Roylance R, Jacobs IJ, Menon U, Schett G, Penninger JM (2017) Aberrant regulation of RANKL\/OPG in women at high risk of developing breast cancer. Oncotarget 8:3811\u20133825","journal-title":"Oncotarget"},{"key":"1093_CR32","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1038\/nature09707","volume":"470","author":"W Tan","year":"2011","unstructured":"Tan W, Zhang W, Strasner A, Grivennikov S, Cheng JQ, Hoffman RM, Karin M (2011) Tumour-infiltrating regulatory T cells stimulate mammary cancer metastasis through RANKL-RANK signalling. Nature 470:548\u2013553","journal-title":"Nature"},{"key":"1093_CR33","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1002\/jbmr.4480","volume":"37","author":"F Pin","year":"2022","unstructured":"Pin F, Jones AJ, Huot JR, Narasimhan A, Zimmers TA, Bonewald LF, Bonetto A (2022) RANKL blockade reduces cachexia and bone loss induced by non-metastatic ovarian cancer in mice. J Bone Miner Res 37:381\u2013396","journal-title":"J Bone Miner Res"},{"key":"1093_CR34","doi-asserted-by":"publisher","first-page":"1842","DOI":"10.1096\/fj.05-4221fje","volume":"19","author":"KE Poole","year":"2005","unstructured":"Poole KE, van Bezooijen RL, Loveridge N, Hamersma H, Papapoulos SE, L\u00f6wik CW, Reeve J (2005) Sclerostin is a delayed secreted product of osteocytes that inhibits bone formation. Faseb j 19:1842\u20131844","journal-title":"Faseb j"},{"key":"1093_CR35","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1146\/annurev-physiol-021119-034332","volume":"82","author":"AG Robling","year":"2020","unstructured":"Robling AG, Bonewald LF (2020) The osteocyte: new insights. Annu Rev Physiol 82:485\u2013506","journal-title":"Annu Rev Physiol"},{"key":"1093_CR36","doi-asserted-by":"publisher","first-page":"1737","DOI":"10.1210\/jc.2011-2958","volume":"97","author":"L Gennari","year":"2012","unstructured":"Gennari L, Merlotti D, Valenti R, Ceccarelli E, Ruvio M, Pietrini MG, Capodarca C, Franci MB, Campagna MS, Calabro A, Cataldo D, Stolakis K, Dotta F, Nuti R (2012) Circulating sclerostin levels and bone turnover in type 1 and type 2 diabetes. J Clin Endocrinol Metab 97:1737\u20131744","journal-title":"J Clin Endocrinol Metab"},{"key":"1093_CR37","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1210\/jc.2011-2186","volume":"97","author":"A Garcia-Martin","year":"2012","unstructured":"Garcia-Martin A, Rozas-Moreno P, Reyes-Garcia R, Morales-Santana S, Garcia-Fontana B, Garcia-Salcedo JA, Munoz-Torres M (2012) Circulating levels of sclerostin are increased in patients with type 2 diabetes mellitus. J Clin Endocrinol Metab 97:234\u2013241","journal-title":"J Clin Endocrinol Metab"},{"key":"1093_CR38","first-page":"470","volume":"21","author":"Y Wu","year":"2017","unstructured":"Wu Y, Xu SY, Liu SY, Xu L, Deng SY, He YB, Xian SC, Liu YH, Ni GX (2017) Upregulated serum sclerostin level in the T2DM patients with femur fracture inhibits the expression of bone formation\/remodeling-associated biomarkers via antagonizing Wnt signaling. Eur Rev Med Pharmacol Sci 21:470\u2013478","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"1093_CR39","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1007\/s00774-013-0524-z","volume":"32","author":"Y Rhee","year":"2014","unstructured":"Rhee Y, Kim WJ, Han KJ, Lim SK, Kim SH (2014) Effect of liver dysfunction on circulating sclerostin. J Bone Miner Metab 32:545\u2013549","journal-title":"J Bone Miner Metab"},{"key":"1093_CR40","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1007\/s00508-019-01595-8","volume":"132","author":"R Wakolbinger","year":"2020","unstructured":"Wakolbinger R, Muschitz C, Wallwitz J, Bodlaj G, Feichtinger X, Schanda JE, Resch H, Baierl A, Pietschmann P (2020) Serum levels of sclerostin reflect altered bone microarchitecture in patients with hepatic cirrhosis. Wien Klin Wochenschr 132:19\u201326","journal-title":"Wien Klin Wochenschr"},{"key":"1093_CR41","doi-asserted-by":"publisher","first-page":"707505","DOI":"10.3389\/fendo.2021.707505","volume":"12","author":"F Zhou","year":"2021","unstructured":"Zhou F, Wang Y, Li Y, Tang M, Wan S, Tian H, Chen X (2021) Decreased sclerostin secretion in humans and mice with nonalcoholic fatty liver disease. Front Endocrinol (Lausanne) 12:707505","journal-title":"Front Endocrinol (Lausanne)"},{"key":"1093_CR42","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1007\/s00774-015-0687-x","volume":"34","author":"SA Polyzos","year":"2016","unstructured":"Polyzos SA, Anastasilakis AD, Kountouras J, Makras P, Papatheodorou A, Kokkoris P, Sakellariou GT, Terpos E (2016) Circulating sclerostin and Dickkopf-1 levels in patients with nonalcoholic fatty liver disease. J Bone Miner Metab 34:447\u2013456","journal-title":"J Bone Miner Metab"},{"key":"1093_CR43","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.bone.2012.04.016","volume":"51","author":"MP Yavropoulou","year":"2012","unstructured":"Yavropoulou MP, van Lierop AH, Hamdy NA, Rizzoli R, Papapoulos SE (2012) Serum sclerostin levels in Paget\u2019s disease and prostate cancer with bone metastases with a wide range of bone turnover. Bone 51:153\u2013157","journal-title":"Bone"},{"key":"1093_CR44","doi-asserted-by":"publisher","first-page":"1466","DOI":"10.1002\/ijc.27342","volume":"131","author":"E Terpos","year":"2012","unstructured":"Terpos E, Christoulas D, Katodritou E, Bratengeier C, Gkotzamanidou M, Michalis E, Delimpasi S, Pouli A, Meletis J, Kastritis E, Zervas K, Dimopoulos MA (2012) Elevated circulating sclerostin correlates with advanced disease features and abnormal bone remodeling in symptomatic myeloma: reduction post-bortezomib monotherapy. Int J Cancer 131:1466\u20131471","journal-title":"Int J Cancer"},{"key":"1093_CR45","doi-asserted-by":"publisher","first-page":"11399","DOI":"10.1038\/s41598-017-11913-7","volume":"7","author":"M Zhu","year":"2017","unstructured":"Zhu M, Liu C, Li S, Zhang S, Yao Q, Song Q (2017) Sclerostin induced tumor growth, bone metastasis and osteolysis in breast cancer. Sci Rep 7:11399","journal-title":"Sci Rep"},{"key":"1093_CR46","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.125543","author":"E Hesse","year":"2019","unstructured":"Hesse E, Schroder S, Brandt D, Pamperin J, Saito H, Taipaleenmaki H (2019) Sclerostin inhibition alleviates breast cancer-induced bone metastases and muscle weakness. JCI Insight. https:\/\/doi.org\/10.1172\/jci.insight.125543","journal-title":"JCI Insight"},{"key":"1093_CR47","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1016\/j.bone.2018.11.002","volume":"120","author":"L Bonewald","year":"2019","unstructured":"Bonewald L (2019) Use it or lose it to age: a review of bone and muscle communication. Bone 120:212\u2013218","journal-title":"Bone"},{"key":"1093_CR48","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1590\/0004-2730000003333","volume":"58","author":"LC Zanatta","year":"2014","unstructured":"Zanatta LC, Boguszewski CL, Borba VZ, Kulak CA (2014) Osteocalcin, energy and glucose metabolism. Arq Bras Endocrinol Metabol 58:444\u2013451","journal-title":"Arq Bras Endocrinol Metabol"},{"key":"1093_CR49","doi-asserted-by":"publisher","first-page":"1694","DOI":"10.1002\/jbmr.4330","volume":"36","author":"H Zeng","year":"2021","unstructured":"Zeng H, Ge J, Xu W, Ma H, Chen L, Xia M, Pan B, Lin H, Wang S, Gao X (2021) Type 2 diabetes is causally associated with reduced serum osteocalcin: a genomewide association and mendelian randomization study. J Bone Miner Res 36:1694\u20131707","journal-title":"J Bone Miner Res"},{"key":"1093_CR50","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgad043","author":"MI Nasser","year":"2023","unstructured":"Nasser MI, Stidsen JV, Hojlund K, Nielsen JS, Eastell R, Frost M (2023) Low bone turnover associates with lower insulin sensitivity in newly diagnosed drug-naive persons with type 2 diabetes. J Clin Endocrinol Metab. https:\/\/doi.org\/10.1210\/clinem\/dgad043","journal-title":"J Clin Endocrinol Metab"},{"key":"1093_CR51","doi-asserted-by":"publisher","first-page":"631","DOI":"10.3109\/00365513.2011.604427","volume":"71","author":"Y Yilmaz","year":"2011","unstructured":"Yilmaz Y, Kurt R, Eren F, Imeryuz N (2011) Serum osteocalcin levels in patients with nonalcoholic fatty liver disease: association with ballooning degeneration. Scand J Clin Lab Invest 71:631\u2013636","journal-title":"Scand J Clin Lab Invest"},{"key":"1093_CR52","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1097\/MEG.0000000000000535","volume":"28","author":"HJ Yang","year":"2016","unstructured":"Yang HJ, Shim SG, Ma BO, Kwak JY (2016) Association of nonalcoholic fatty liver disease with bone mineral density and serum osteocalcin levels in Korean men. Eur J Gastroenterol Hepatol 28:338\u2013344","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"1093_CR53","doi-asserted-by":"publisher","first-page":"1497","DOI":"10.1038\/aps.2015.81","volume":"36","author":"YQ Luo","year":"2015","unstructured":"Luo YQ, Ma XJ, Hao YP, Pan XP, Xu YT, Xiong Q, Bao YQ, Jia WP (2015) Inverse relationship between serum osteocalcin levels and nonalcoholic fatty liver disease in postmenopausal Chinese women with normal blood glucose levels. Acta Pharmacol Sin 36:1497\u20131502","journal-title":"Acta Pharmacol Sin"},{"key":"1093_CR54","doi-asserted-by":"publisher","first-page":"101397","DOI":"10.1016\/j.diabet.2022.101397","volume":"49","author":"D Fang","year":"2022","unstructured":"Fang D, Yin H, Ji X, Sun H, Zhao X, Bi Y, Gu T (2022) Low levels of osteocalcin, but not CTX or P1NP, are associated with nonalcoholic hepatic steatosis and steatohepatitis. Diabetes Metab 49:101397","journal-title":"Diabetes Metab"},{"key":"1093_CR55","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1007\/s12032-009-9214-z","volume":"27","author":"EM Karapanagiotou","year":"2010","unstructured":"Karapanagiotou EM, Terpos E, Dilana KD, Alamara C, Gkiozos I, Polyzos A, Syrigos KN (2010) Serum bone turnover markers may be involved in the metastatic potential of lung cancer patients. Med Oncol 27:332\u2013338","journal-title":"Med Oncol"},{"key":"1093_CR56","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1007\/s10147-011-0266-7","volume":"17","author":"SB Bayrak","year":"2012","unstructured":"Bayrak SB, Ceylan E, Serter M, Karadag F, Demir E, Cildag O (2012) The clinical importance of bone metabolic markers in detecting bone metastasis of lung cancer. Int J Clin Oncol 17:112\u2013118","journal-title":"Int J Clin Oncol"},{"key":"1093_CR57","doi-asserted-by":"publisher","first-page":"6209","DOI":"10.21608\/ejhm.2022.268114","volume":"89","author":"MS Ahmeid","year":"2022","unstructured":"Ahmeid MS, Hassan WN, Awa NA (2022) Evaluation of the serum level of osteocalcin in breast cancer patients, and its association with estrogen and progesterone receptors. Egypt J Hosp Med 89:6209\u20136213","journal-title":"Egypt J Hosp Med"},{"key":"1093_CR58","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1002\/jbmr.4227","volume":"36","author":"M Xia","year":"2021","unstructured":"Xia M, Rong S, Zhu X, Yan H, Chang X, Sun X, Zeng H, Li X, Zhang L, Chen L, Wu L, Ma H, Hu Y, He W, Gao J, Pan B, Hu X, Lin H, Bian H, Gao X (2021) Osteocalcin and non-alcoholic fatty liver disease: lessons from two population-based cohorts and animal models. J Bone Miner Res 36:712\u2013728","journal-title":"J Bone Miner Res"},{"key":"1093_CR59","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1002\/jbmr.320","volume":"26","author":"LF Bonewald","year":"2011","unstructured":"Bonewald LF (2011) The amazing osteocyte. J Bone Miner Res 26:229\u2013238","journal-title":"J Bone Miner Res"},{"key":"1093_CR60","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1186\/s12933-017-0559-x","volume":"16","author":"X He","year":"2017","unstructured":"He X, Hu X, Ma X, Su H, Ying L, Peng J, Pan X, Bao Y, Zhou J, Jia W (2017) Elevated serum fibroblast growth factor 23 levels as an indicator of lower extremity atherosclerotic disease in Chinese patients with type 2 diabetes mellitus. Cardiovasc Diabetol 16:77","journal-title":"Cardiovasc Diabetol"},{"key":"1093_CR61","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1055\/a-0813-3164","volume":"51","author":"A Gateva","year":"2019","unstructured":"Gateva A, Assyov Y, Tsakova A, Kamenov Z (2019) Prediabetes is characterized by higher FGF23 levels and higher prevalence of vitamin D deficiency compared to normal glucose tolerance subjects. Horm Metab Res 51:106\u2013111","journal-title":"Horm Metab Res"},{"key":"1093_CR62","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1111\/1440-1681.12933","volume":"45","author":"X He","year":"2018","unstructured":"He X, Shen Y, Ma X, Ying L, Peng J, Pan X, Bao Y, Zhou J (2018) The association of serum FGF23 and non-alcoholic fatty liver disease is independent of vitamin D in type 2 diabetes patients. Clin Exp Pharmacol Physiol 45:668\u2013674","journal-title":"Clin Exp Pharmacol Physiol"},{"key":"1093_CR63","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1016\/j.bone.2006.01.163","volume":"39","author":"I Stewart","year":"2006","unstructured":"Stewart I, Roddie C, Gill A, Clarkson A, Mirams M, Coyle L, Ward C, Clifton-Bligh P, Robinson BG, Mason RS, Clifton-Bligh RJ (2006) Elevated serum FGF23 concentrations in plasma cell dyscrasias. Bone 39:369\u2013376","journal-title":"Bone"},{"key":"1093_CR64","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1016\/S0025-6196(11)61528-0","volume":"80","author":"PJ Tebben","year":"2005","unstructured":"Tebben PJ, Kalli KR, Cliby WA, Hartmann LC, Grande JP, Singh RJ, Kumar R (2005) Elevated fibroblast growth factor 23 in women with malignant ovarian tumors. Mayo Clin Proc 80:745\u2013751","journal-title":"Mayo Clin Proc"},{"key":"1093_CR65","first-page":"471","volume":"4","author":"R Cekin","year":"2020","unstructured":"Cekin R et al (2020) The clinical importance of fibroblast growth factor 23 on breast cancer patients. J Med Invest 4:471\u2013476","journal-title":"J Med Invest"},{"key":"1093_CR66","doi-asserted-by":"publisher","first-page":"17291","DOI":"10.18632\/oncotarget.4174","volume":"6","author":"S Feng","year":"2015","unstructured":"Feng S, Wang J, Zhang Y, Creighton CJ, Ittmann M (2015) FGF23 promotes prostate cancer progression. Oncotarget 6:17291\u201317301","journal-title":"Oncotarget"},{"key":"1093_CR67","doi-asserted-by":"publisher","first-page":"223","DOI":"10.2174\/1872208311206030223","volume":"6","author":"C Mo","year":"2012","unstructured":"Mo C, Romero-Suarez S, Bonewald L, Johnson M, Brotto M (2012) Prostaglandin E2: from clinical applications to its potential role in bone- muscle crosstalk and myogenic differentiation. Recent Pat Biotechnol 6:223\u2013229","journal-title":"Recent Pat Biotechnol"},{"key":"1093_CR68","doi-asserted-by":"publisher","first-page":"106361","DOI":"10.1016\/j.prostaglandins.2019.106361","volume":"145","author":"SC Pawelzik","year":"2019","unstructured":"Pawelzik SC, Avignon A, Idborg H, Boegner C, Stanke-Labesque F, Jakobsson PJ, Sultan A, Back M (2019) Urinary prostaglandin D(2) and E(2) metabolites associate with abdominal obesity, glucose metabolism, and triglycerides in obese subjects. Prostaglandins Other Lipid Mediat 145:106361","journal-title":"Prostaglandins Other Lipid Mediat"},{"key":"1093_CR69","doi-asserted-by":"publisher","first-page":"1234","DOI":"10.3390\/metabo12121234","volume":"12","author":"RJ Fenske","year":"2022","unstructured":"Fenske RJ, Weeks AM, Daniels M, Nall R, Pabich S, Brill AL, Peter DC, Punt M, Cox ED, Davis DB, Kimple ME (2022) Plasma prostaglandin E(2) metabolite levels predict type 2 diabetes status and one-year therapeutic response independent of clinical markers of inflammation. Metabolites 12:1234","journal-title":"Metabolites"},{"key":"1093_CR70","doi-asserted-by":"publisher","first-page":"16127","DOI":"10.1038\/s41598-018-34633-y","volume":"8","author":"J Henkel","year":"2018","unstructured":"Henkel J, Coleman CD, Schraplau A, Johrens K, Weiss TS, Jonas W, Schurmann A, Puschel GP (2018) Augmented liver inflammation in a microsomal prostaglandin E synthase 1 (mPGES-1)-deficient diet-induced mouse NASH model. Sci Rep 8:16127","journal-title":"Sci Rep"},{"key":"1093_CR71","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1194\/jlr.P055640","volume":"56","author":"R Loomba","year":"2015","unstructured":"Loomba R, Quehenberger O, Armando A, Dennis EA (2015) Polyunsaturated fatty acid metabolites as novel lipidomic biomarkers for noninvasive diagnosis of nonalcoholic steatohepatitis. J Lipid Res 56:185\u2013192","journal-title":"J Lipid Res"},{"key":"1093_CR72","doi-asserted-by":"publisher","first-page":"2313","DOI":"10.3390\/cells11152313","volume":"11","author":"L Goodla","year":"2022","unstructured":"Goodla L, Xue X (2022) The role of inflammatory mediators in colorectal cancer hepatic metastasis. Cells 11:2313","journal-title":"Cells"},{"key":"1093_CR73","doi-asserted-by":"publisher","first-page":"5498","DOI":"10.1182\/blood-2011-07-365825","volume":"118","author":"N Obermajer","year":"2011","unstructured":"Obermajer N, Muthuswamy R, Lesnock J, Edwards RP, Kalinski P (2011) Positive feedback between PGE2 and COX2 redirects the differentiation of human dendritic cells toward stable myeloid-derived suppressor cells. Blood 118:5498\u20135505","journal-title":"Blood"},{"key":"1093_CR74","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1097\/CEJ.0000000000000583","volume":"30","author":"F Wang","year":"2021","unstructured":"Wang F, Wang M, Yin H, Long Z, Zhu L, Yu H, Sun H, Bi H, Li S, Zhao Y, Dong X, Zhou J (2021) Association between plasma prostaglandin E2 level and colorectal cancer. Eur J Cancer Prev 30:59\u201368","journal-title":"Eur J Cancer Prev"},{"key":"1093_CR75","first-page":"261","volume":"1990","author":"LF Bonewald","year":"1990","unstructured":"Bonewald LF, Mundy GR (1990) Role of transforming growth factor-beta in bone remodeling. Clin Orthop Relat Res 1990:261\u2013276","journal-title":"Clin Orthop Relat Res"},{"key":"1093_CR76","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1007\/978-1-4939-2966-5_18","volume":"1344","author":"JL Crane","year":"2016","unstructured":"Crane JL, Xian L, Cao X (2016) Role of TGF-\u03b2 signaling in coupling bone remodeling. Methods Mol Biol 1344:287\u2013300","journal-title":"Methods Mol Biol"},{"key":"1093_CR77","doi-asserted-by":"publisher","first-page":"5199","DOI":"10.3390\/ijms15045199","volume":"15","author":"B Herrera","year":"2014","unstructured":"Herrera B, Dooley S, Breitkopf-Heinlein K (2014) Potential roles of bone morphogenetic protein (BMP)-9 in human liver diseases. Int J Mol Sci 15:5199\u20135220","journal-title":"Int J Mol Sci"},{"key":"1093_CR78","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a021899","author":"T Katagiri","year":"2016","unstructured":"Katagiri T, Watabe T (2016) Bone morphogenetic proteins. Cold Spring Harb Perspect Biol. https:\/\/doi.org\/10.1101\/cshperspect.a021899","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"1093_CR79","doi-asserted-by":"publisher","first-page":"39","DOI":"10.3390\/ijms19010039","volume":"19","author":"B Herrera","year":"2017","unstructured":"Herrera B, Addante A, S\u00e1nchez A (2017) BMP signalling at the crossroad of liver fibrosis and regeneration. Int J Mol Sci 19:39","journal-title":"Int J Mol Sci"},{"key":"1093_CR80","doi-asserted-by":"publisher","first-page":"e6583","DOI":"10.1097\/MD.0000000000006583","volume":"96","author":"YC Qiao","year":"2017","unstructured":"Qiao YC, Chen YL, Pan YH, Ling W, Tian F, Zhang XX, Zhao HL (2017) Changes of transforming growth factor beta 1 in patients with type 2 diabetes and diabetic nephropathy: a PRISMA-compliant systematic review and meta-analysis. Medicine (Baltimore) 96:e6583","journal-title":"Medicine (Baltimore)"},{"key":"1093_CR81","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1186\/1479-5876-6-72","volume":"6","author":"G Tarantino","year":"2008","unstructured":"Tarantino G, Conca P, Riccio A, Tarantino M, Di Minno MN, Chianese D, Pasanisi F, Contaldo F, Scopacasa F, Capone D (2008) Enhanced serum concentrations of transforming growth factor-beta1 in simple fatty liver: is it really benign? J Transl Med 6:72","journal-title":"J Transl Med"},{"key":"1093_CR82","doi-asserted-by":"publisher","first-page":"880298","DOI":"10.3389\/fimmu.2022.880298","volume":"13","author":"Y Duan","year":"2022","unstructured":"Duan Y, Pan X, Luo J, Xiao X, Li J, Bestman PL, Luo M (2022) Association of inflammatory cytokines with non-alcoholic fatty liver disease. Front Immunol 13:880298","journal-title":"Front Immunol"},{"key":"1093_CR83","doi-asserted-by":"publisher","first-page":"2219","DOI":"10.1111\/febs.13665","volume":"283","author":"I Fabregat","year":"2016","unstructured":"Fabregat I, Moreno-Caceres J, Sanchez A, Dooley S, Dewidar B, Giannelli G, Ten Dijke P, Consortium IL (2016) TGF-beta signalling and liver disease. FEBS J 283:2219\u20132232","journal-title":"FEBS J"},{"key":"1093_CR84","doi-asserted-by":"publisher","first-page":"84695","DOI":"10.18632\/oncotarget.13218","volume":"7","author":"WQ Lu","year":"2016","unstructured":"Lu WQ, Qiu JL, Huang ZL, Liu HY (2016) Enhanced circulating transforming growth factor beta 1 is causally associated with an increased risk of hepatocellular carcinoma: a mendelian randomization meta-analysis. Oncotarget 7:84695\u201384704","journal-title":"Oncotarget"},{"key":"1093_CR85","doi-asserted-by":"publisher","first-page":"34387","DOI":"10.18632\/oncotarget.16166","volume":"8","author":"L Peng","year":"2017","unstructured":"Peng L, Yuan XQ, Zhang CY, Ye F, Zhou HF, Li WL, Liu ZY, Zhang YQ, Pan X, Li GC (2017) High TGF-beta1 expression predicts poor disease prognosis in hepatocellular carcinoma patients. Oncotarget 8:34387\u201334397","journal-title":"Oncotarget"},{"key":"1093_CR86","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1023\/A:1013177011767","volume":"20","author":"BA Teicher","year":"2001","unstructured":"Teicher BA (2001) Malignant cells, directors of the malignant process: role of transforming growth factor-beta. Cancer Metastasis Rev 20:133\u2013143","journal-title":"Cancer Metastasis Rev"},{"key":"1093_CR87","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1042\/CS20160543","volume":"131","author":"Y Luo","year":"2017","unstructured":"Luo Y, Li L, Xu X, Wu T, Yang M, Zhang C, Mou H, Zhou T, Jia Y, Cai C, Liu H, Yang G, Zhang X (2017) Decreased circulating BMP-9 levels in patients with Type 2 diabetes is a signature of insulin resistance. Clin Sci (Lond) 131:239\u2013246","journal-title":"Clin Sci (Lond)"},{"key":"1093_CR88","doi-asserted-by":"publisher","first-page":"897","DOI":"10.3892\/etm.2021.10329","volume":"22","author":"JM Zhang","year":"2021","unstructured":"Zhang JM, Yu RQ, Wu FZ, Qiao L, Wu XR, Fu YJ, Liang YF, Pang Y, Xie CY (2021) BMP-2 alleviates heart failure with type 2 diabetes mellitus and doxorubicin-induced AC16 cell injury by inhibiting NLRP3 inflammasome-mediated pyroptosis. Exp Ther Med 22:897","journal-title":"Exp Ther Med"},{"key":"1093_CR89","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1186\/s12933-015-0214-3","volume":"14","author":"M Zhang","year":"2015","unstructured":"Zhang M, Sara JD, Wang FL, Liu LP, Su LX, Zhe J, Wu X, Liu JH (2015) Increased plasma BMP-2 levels are associated with atherosclerosis burden and coronary calcification in type 2 diabetic patients. Cardiovasc Diabetol 14:64","journal-title":"Cardiovasc Diabetol"},{"key":"1093_CR90","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1186\/s40364-022-00383-3","volume":"10","author":"P Maranon","year":"2022","unstructured":"Maranon P, Fernandez-Garcia CE, Isaza SC, Rey E, Gallego-Duran R, Montero-Vallejo R, de Cia JR, Ampuero J, Romero-Gomez M, Garcia-Monzon C, Gonzalez-Rodriguez A (2022) Bone morphogenetic protein 2 is a new molecular target linked to non-alcoholic fatty liver disease with potential value as non-invasive screening tool. Biomark Res 10:35","journal-title":"Biomark Res"},{"key":"1093_CR91","doi-asserted-by":"publisher","first-page":"3404","DOI":"10.1007\/s10620-007-9758-8","volume":"52","author":"F Tacke","year":"2007","unstructured":"Tacke F, Gabele E, Bataille F, Schwabe RF, Hellerbrand C, Klebl F, Straub RH, Luedde T, Manns MP, Trautwein C, Brenner DA, Scholmerich J, Schnabl B (2007) Bone morphogenetic protein 7 is elevated in patients with chronic liver disease and exerts fibrogenic effects on human hepatic stellate cells. Dig Dis Sci 52:3404\u20133415","journal-title":"Dig Dis Sci"},{"key":"1093_CR92","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1016\/j.bbadis.2017.12.008","volume":"1864","author":"P Li","year":"2018","unstructured":"Li P, Li Y, Zhu L, Yang Z, He J, Wang L, Shang Q, Pan H, Wang H, Ma X, Li B, Fan X, Ge S, Jia R, Zhang H (2018) Targeting secreted cytokine BMP9 gates the attenuation of hepatic fibrosis. Biochim Biophys Acta Mol Basis Dis 1864:709\u2013720","journal-title":"Biochim Biophys Acta Mol Basis Dis"},{"key":"1093_CR93","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1007\/s00535-019-01579-5","volume":"54","author":"Y Mano","year":"2019","unstructured":"Mano Y, Yoshio S, Shoji H, Tomonari S, Aoki Y, Aoyanagi N, Okamoto T, Matsuura Y, Osawa Y, Kimura K, Yugawa K, Wang H, Oda Y, Yoshizumi T, Maehara Y, Kanto T (2019) Bone morphogenetic protein 4 provides cancer-supportive phenotypes to liver fibroblasts in patients with hepatocellular carcinoma. J Gastroenterol 54:1007\u20131018","journal-title":"J Gastroenterol"},{"key":"1093_CR94","doi-asserted-by":"publisher","first-page":"7088","DOI":"10.1073\/pnas.96.12.7088","volume":"96","author":"K Sj\u00f6gren","year":"1999","unstructured":"Sj\u00f6gren K, Liu JL, Blad K, Skrtic S, Vidal O, Wallenius V, LeRoith D, T\u00f6rnell J, Isaksson OG, Jansson JO, Ohlsson C (1999) Liver-derived insulin-like growth factor I (IGF-I) is the principal source of IGF-I in blood but is not required for postnatal body growth in mice. Proc Natl Acad Sci U S A 96:7088\u20137092","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1093_CR95","doi-asserted-by":"publisher","first-page":"2741","DOI":"10.1210\/endo.136.6.7750499","volume":"136","author":"E Wang","year":"1995","unstructured":"Wang E, Wang J, Chin E, Zhou J, Bondy CA (1995) Cellular patterns of insulin-like growth factor system gene expression in murine chondrogenesis and osteogenesis. Endocrinology 136:2741\u20132751","journal-title":"Endocrinology"},{"key":"1093_CR96","first-page":"E937","volume":"270","author":"JM Lean","year":"1996","unstructured":"Lean JM, Mackay AG, Chow JW, Chambers TJ (1996) Osteocytic expression of mRNA for c-fos and IGF-I: an immediate early gene response to an osteogenic stimulus. Am J Physiol 270:E937-945","journal-title":"Am J Physiol"},{"key":"1093_CR97","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.bone.2012.09.027","volume":"52","author":"MH Sheng","year":"2013","unstructured":"Sheng MH, Zhou XD, Bonewald LF, Baylink DJ, Lau KH (2013) Disruption of the insulin-like growth factor-1 gene in osteocytes impairs developmental bone growth in mice. Bone 52:133\u2013144","journal-title":"Bone"},{"key":"1093_CR98","doi-asserted-by":"publisher","first-page":"143","DOI":"10.2174\/1874467211205020143","volume":"5","author":"KE Govoni","year":"2012","unstructured":"Govoni KE (2012) Insulin-like growth factor-I molecular pathways in osteoblasts: potential targets for pharmacological manipulation. Curr Mol Pharmacol 5:143\u2013152","journal-title":"Curr Mol Pharmacol"},{"key":"1093_CR99","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1007\/s00198-020-05790-6","volume":"32","author":"F Lv","year":"2021","unstructured":"Lv F, Cai X, Zhang R, Zhou L, Zhou X, Han X, Ji L (2021) Sex-specific associations of serum insulin-like growth factor-1 with bone density and risk of fractures in Chinese patients with type 2 diabetes. Osteoporos Int 32:1165\u20131173","journal-title":"Osteoporos Int"},{"key":"1093_CR100","doi-asserted-by":"publisher","first-page":"1308","DOI":"10.3390\/ijms19051308","volume":"19","author":"A Adamek","year":"2018","unstructured":"Adamek A, Kasprzak A (2018) Insulin-like growth factor (IGF) system in liver diseases. Int J Mol Sci 19:1308","journal-title":"Int J Mol Sci"},{"key":"1093_CR101","doi-asserted-by":"publisher","first-page":"4014","DOI":"10.1158\/0008-5472.CAN-20-1281","volume":"80","author":"A Knuppel","year":"2020","unstructured":"Knuppel A, Fensom GK, Watts EL, Gunter MJ, Murphy N, Papier K, Perez-Cornago A, Schmidt JA, Smith Byrne K, Travis RC, Key TJ (2020) Circulating insulin-like growth factor-I concentrations and risk of 30 cancers: prospective analyses in UK biobank. Cancer Res 80:4014\u20134021","journal-title":"Cancer Res"},{"key":"1093_CR102","doi-asserted-by":"publisher","first-page":"2947","DOI":"10.1210\/jc.2012-2142","volume":"97","author":"JJ Wysolmerski","year":"2012","unstructured":"Wysolmerski JJ (2012) Parathyroid hormone-related protein: an update. J Clin Endocrinol Metab 97:2947\u20132956","journal-title":"J Clin Endocrinol Metab"},{"key":"1093_CR103","first-page":"510","volume":"90","author":"NK Lai","year":"2019","unstructured":"Lai NK, Martinez D (2019) Physiological roles of parathyroid hormone-related protein. Acta Biomed 90:510\u2013516","journal-title":"Acta Biomed"},{"key":"1093_CR104","doi-asserted-by":"publisher","first-page":"2322","DOI":"10.1172\/JCI26239","volume":"115","author":"TJ Martin","year":"2005","unstructured":"Martin TJ (2005) Osteoblast-derived PTHrP is a physiological regulator of bone formation. J Clin Invest 115:2322\u20132324","journal-title":"J Clin Invest"},{"key":"1093_CR105","doi-asserted-by":"publisher","first-page":"1761","DOI":"10.1002\/jbmr.3167","volume":"32","author":"K J\u00e4hn","year":"2017","unstructured":"J\u00e4hn K, Kelkar S, Zhao H, Xie Y, Tiede-Lewis LM, Dusevich V, Dallas SL, Bonewald LF (2017) Osteocytes acidify their microenvironment in response to PTHrP in vitro and in lactating mice in vivo. J Bone Miner Res 32:1761\u20131772","journal-title":"J Bone Miner Res"},{"key":"1093_CR106","doi-asserted-by":"publisher","first-page":"E826","DOI":"10.1210\/jc.2014-4132","volume":"100","author":"MM Roca-Rodriguez","year":"2015","unstructured":"Roca-Rodriguez MM, El Bekay R, Garrido-Sanchez L, Gomez-Serrano M, Coin-Araguez L, Oliva-Olivera W, Lhamyani S, Clemente-Postigo M, Garcia-Santos E, de Luna DR, Yubero-Serrano EM, Fernandez Real JM, Peral B, Tinahones FJ (2015) Parathyroid hormone-related protein, human adipose-derived stem cells adipogenic capacity and healthy obesity. J Clin Endocrinol Metab 100:E826-835","journal-title":"J Clin Endocrinol Metab"},{"key":"1093_CR107","doi-asserted-by":"publisher","first-page":"162846","DOI":"10.1155\/2013\/162846","volume":"2013","author":"M Romero","year":"2013","unstructured":"Romero M, Ortega A, Olea N, Arenas MI, Izquierdo A, Bover J, Esbrit P, Bosch RJ (2013) Novel role of parathyroid hormone-related protein in the pathophysiology of the diabetic kidney: evidence from experimental and human diabetic nephropathy. J Diabetes Res 2013:162846","journal-title":"J Diabetes Res"},{"key":"1093_CR108","doi-asserted-by":"publisher","first-page":"291027","DOI":"10.1155\/2009\/291027","volume":"2009","author":"I Legakis","year":"2009","unstructured":"Legakis I, Mantouridis T (2009) Positive correlation of PTH-related peptide with glucose in type 2 diabetes. Exp Diabetes Res 2009:291027","journal-title":"Exp Diabetes Res"},{"key":"1093_CR109","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1023\/A:1005435424853","volume":"45","author":"E Fabrega","year":"2000","unstructured":"Fabrega E, Rivero M, Pons-Romero F, Garcia-Unzueta MT, Amado JA (2000) Parathyroid hormone-related protein in liver cirrhosis. Dig Dis Sci 45:703","journal-title":"Dig Dis Sci"},{"key":"1093_CR110","doi-asserted-by":"publisher","first-page":"644303","DOI":"10.3389\/fonc.2021.644303","volume":"11","author":"CM Edwards","year":"2021","unstructured":"Edwards CM, Johnson RW (2021) From good to bad: the opposing effects of PTHrP on tumor growth, dormancy, and metastasis throughout cancer progression. Front Oncol 11:644303","journal-title":"Front Oncol"},{"key":"1093_CR111","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1210\/jc.2015-3785","volume":"101","author":"N Hong","year":"2016","unstructured":"Hong N, Yoon HJ, Lee YH, Kim HR, Lee BW, Rhee Y, Kang ES, Cha BS, Lee HC (2016) Serum PTHrP predicts weight loss in cancer patients independent of hypercalcemia, inflammation, and tumor burden. J Clin Endocrinol Metab 101:1207\u20131214","journal-title":"J Clin Endocrinol Metab"},{"key":"1093_CR112","doi-asserted-by":"publisher","first-page":"C663","DOI":"10.1152\/ajpcell.00285.2015","volume":"310","author":"SS Dufresne","year":"2016","unstructured":"Dufresne SS, Dumont NA, Boulanger-Piette A, Fajardo VA, Gamu D, Kake-Guena SA, David RO, Bouchard P, Lavergne \u00c9, Penninger JM, Pape PC, Tupling AR, Frenette J (2016) Muscle RANK is a key regulator of Ca2+ storage, SERCA activity, and function of fast-twitch skeletal muscles. Am J Physiol Cell Physiol 310:C663-672","journal-title":"Am J Physiol Cell Physiol"},{"key":"1093_CR113","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1093\/hmg\/ddz312","volume":"29","author":"D Hamoudi","year":"2020","unstructured":"Hamoudi D, Bouredji Z, Marcadet L, Yagita H, Landry LB, Argaw A, Frenette J (2020) Muscle weakness and selective muscle atrophy in osteoprotegerin-deficient mice. Hum Mol Genet 29:483\u2013494","journal-title":"Hum Mol Genet"},{"key":"1093_CR114","doi-asserted-by":"publisher","first-page":"3101","DOI":"10.1093\/hmg\/ddz124","volume":"28","author":"D Hamoudi","year":"2019","unstructured":"Hamoudi D, Marcadet L, Piette Boulanger A, Yagita H, Bouredji Z, Argaw A, Frenette J (2019) An anti-RANKL treatment reduces muscle inflammation and dysfunction and strengthens bone in dystrophic mice. Hum Mol Genet 28:3101\u20133112","journal-title":"Hum Mol Genet"},{"key":"1093_CR115","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1165\/rcmb.2020-0449OC","volume":"64","author":"J Xiong","year":"2021","unstructured":"Xiong J, Le Y, Rao Y, Zhou L, Hu Y, Guo S, Sun Y (2021) RANKL mediates muscle atrophy and dysfunction in a cigarette smoke-induced model of chronic obstructive pulmonary disease. Am J Respir Cell Mol Biol 64:617\u2013628","journal-title":"Am J Respir Cell Mol Biol"},{"key":"1093_CR116","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1002\/jbm4.10015","volume":"1","author":"J Huang","year":"2017","unstructured":"Huang J, Romero-Suarez S, Lara N, Mo C, Kaja S, Brotto L, Dallas SL, Johnson ML, J\u00e4hn K, Bonewald LF, Brotto M (2017) Crosstalk between MLO-Y4 osteocytes and C2C12 muscle cells is mediated by the Wnt\/\u03b2-catenin pathway. JBMR Plus 1:86\u2013100","journal-title":"JBMR Plus"},{"key":"1093_CR117","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1515\/jpem-2020-0662","volume":"34","author":"J J\u00fcrim\u00e4e","year":"2021","unstructured":"J\u00fcrim\u00e4e J, Karvelyte V, Remmel L, Tamm AL, Purge P, Gruodyte-Raciene R, Kamandulis S, Maasalu K, Gracia-Marco L, Tillmann V (2021) Serum sclerostin concentration is associated with specific adipose, muscle and bone tissue markers in lean adolescent females with increased physical activity. J Pediatr Endocrinol Metab 34:755\u2013761","journal-title":"J Pediatr Endocrinol Metab"},{"key":"1093_CR118","doi-asserted-by":"publisher","first-page":"115053","DOI":"10.1016\/j.bone.2019.115053","volume":"128","author":"JA Kim","year":"2019","unstructured":"Kim JA, Roh E, Hong SH, Lee YB, Kim NH, Yoo HJ, Seo JA, Kim NH, Kim SG, Baik SH, Choi KM (2019) Association of serum sclerostin levels with low skeletal muscle mass: the Korean sarcopenic obesity study (KSOS). Bone 128:115053","journal-title":"Bone"},{"key":"1093_CR119","doi-asserted-by":"publisher","first-page":"C853","DOI":"10.1152\/ajpcell.00093.2005","volume":"289","author":"DD Armstrong","year":"2005","unstructured":"Armstrong DD, Esser KA (2005) Wnt\/beta-catenin signaling activates growth-control genes during overload-induced skeletal muscle hypertrophy. Am J Physiol Cell Physiol 289:C853-859","journal-title":"Am J Physiol Cell Physiol"},{"key":"1093_CR120","doi-asserted-by":"publisher","first-page":"e1008714","DOI":"10.1371\/journal.pgen.1008714","volume":"16","author":"SC Manolagas","year":"2020","unstructured":"Manolagas SC (2020) Osteocalcin promotes bone mineralization but is not a hormone. PLoS Genet 16:e1008714","journal-title":"PLoS Genet"},{"key":"1093_CR121","doi-asserted-by":"publisher","first-page":"7513","DOI":"10.3390\/ijms21207513","volume":"21","author":"T Komori","year":"2020","unstructured":"Komori T (2020) Functions of osteocalcin in bone, pancreas, testis, and muscle. Int J Mol Sci 21:7513","journal-title":"Int J Mol Sci"},{"key":"1093_CR122","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.bone.2017.04.006","volume":"115","author":"G Karsenty","year":"2018","unstructured":"Karsenty G, Mera P (2018) Molecular bases of the crosstalk between bone and muscle. Bone 115:43\u201349","journal-title":"Bone"},{"key":"1093_CR123","doi-asserted-by":"publisher","first-page":"e1008586","DOI":"10.1371\/journal.pgen.1008586","volume":"16","author":"T Moriishi","year":"2020","unstructured":"Moriishi T, Ozasa R, Ishimoto T, Nakano T, Hasegawa T, Miyazaki T, Liu W, Fukuyama R, Wang Y, Komori H, Qin X, Amizuka N, Komori T (2020) Osteocalcin is necessary for the alignment of apatite crystallites, but not glucose metabolism, testosterone synthesis, or muscle mass. PLoS Genet 16:e1008586","journal-title":"PLoS Genet"},{"key":"1093_CR124","doi-asserted-by":"publisher","first-page":"e1008361","DOI":"10.1371\/journal.pgen.1008361","volume":"16","author":"CR Diegel","year":"2020","unstructured":"Diegel CR, Hann S, Ayturk UM, Hu JCW, Lim KE, Droscha CJ, Madaj ZB, Foxa GE, Izaguirre I, Transgenics Core VVA, Paracha N, Pidhaynyy B, Dowd TL, Robling AG, Warman ML, Williams BO (2020) An osteocalcin-deficient mouse strain without endocrine abnormalities. PLoS Genet 16:e1008361","journal-title":"PLoS Genet"},{"key":"1093_CR125","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.1016\/j.molmet.2016.07.002","volume":"5","author":"P Mera","year":"2016","unstructured":"Mera P, Laue K, Wei J, Berger JM, Karsenty G (2016) Osteocalcin is necessary and sufficient to maintain muscle mass in older mice. Mol Metab 5:1042\u20131047","journal-title":"Mol Metab"},{"key":"1093_CR126","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.1016\/j.cmet.2016.05.004","volume":"23","author":"P Mera","year":"2016","unstructured":"Mera P, Laue K, Ferron M, Confavreux C, Wei J, Gal\u00e1n-D\u00edez M, Lacampagne A, Mitchell SJ, Mattison JA, Chen Y, Bacchetta J, Szulc P, Kitsis RN, de Cabo R, Friedman RA, Torsitano C, McGraw TE, Puchowicz M, Kurland I, Karsenty G (2016) Osteocalcin signaling in myofibers is necessary and sufficient for optimum adaptation to exercise. Cell Metab 23:1078\u20131092","journal-title":"Cell Metab"},{"key":"1093_CR127","doi-asserted-by":"publisher","first-page":"1517","DOI":"10.1002\/jbmr.3731","volume":"34","author":"X Lin","year":"2019","unstructured":"Lin X, Parker L, McLennan E, Hayes A, McConell G, Brennan-Speranza TC, Levinger I (2019) Undercarboxylated osteocalcin improves insulin-stimulated glucose uptake in muscles of corticosterone-treated mice. J Bone Miner Res 34:1517\u20131530","journal-title":"J Bone Miner Res"},{"key":"1093_CR128","doi-asserted-by":"publisher","first-page":"12062","DOI":"10.1038\/s41598-021-91496-6","volume":"11","author":"Y Si","year":"2021","unstructured":"Si Y, Kazamel M, Benatar M, Wuu J, Kwon Y, Kwan T, Jiang N, Kentrup D, Faul C, Alesce L, King PH (2021) FGF23, a novel muscle biomarker detected in the early stages of ALS. Sci Rep 11:12062","journal-title":"Sci Rep"},{"key":"1093_CR129","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1111\/nep.12333","volume":"19","author":"H Fukasawa","year":"2014","unstructured":"Fukasawa H, Ishigaki S, Kinoshita-Katahashi N, Niwa H, Yasuda H, Kumagai H, Furuya R (2014) Plasma levels of fibroblast growth factor-23 are associated with muscle mass in haemodialysis patients. Nephrology (Carlton) 19:784\u2013790","journal-title":"Nephrology (Carlton)"},{"key":"1093_CR130","doi-asserted-by":"publisher","first-page":"E594","DOI":"10.1152\/ajpendo.00343.2017","volume":"315","author":"KG Avin","year":"2018","unstructured":"Avin KG, Vallejo JA, Chen NX, Wang K, Touchberry CD, Brotto M, Dallas SL, Moe SM, Wacker MJ (2018) Fibroblast growth factor 23 does not directly influence skeletal muscle cell proliferation and differentiation or ex vivo muscle contractility. Am J Physiol Endocrinol Metab 315:E594-e604","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"1093_CR131","doi-asserted-by":"publisher","first-page":"116004","DOI":"10.1016\/j.bone.2021.116004","volume":"150","author":"A Gladding","year":"2021","unstructured":"Gladding A, Szymczuk V, Auble BA, Boyce AM (2021) Burosumab treatment for fibrous dysplasia. Bone 150:116004","journal-title":"Bone"},{"key":"1093_CR132","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1080\/15384101.2015.1026520","volume":"14","author":"C Mo","year":"2015","unstructured":"Mo C, Zhao R, Vallejo J, Igwe O, Bonewald L, Wetmore L, Brotto M (2015) Prostaglandin E2 promotes proliferation of skeletal muscle myoblasts via EP4 receptor activation. Cell Cycle 14:1507\u20131516","journal-title":"Cell Cycle"},{"key":"1093_CR133","doi-asserted-by":"publisher","DOI":"10.1126\/science.abc8059","author":"AR Palla","year":"2021","unstructured":"Palla AR, Ravichandran M, Wang YX, Alexandrova L, Yang AV, Kraft P, Holbrook CA, Sch\u00fcrch CM, Ho ATV, Blau HM (2021) Inhibition of prostaglandin-degrading enzyme 15-PGDH rejuvenates aged muscle mass and strength. Science. https:\/\/doi.org\/10.1126\/science.abc8059","journal-title":"Science"},{"key":"1093_CR134","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23031167","author":"GL Klein","year":"2022","unstructured":"Klein GL (2022) Transforming growth factor-beta in skeletal muscle wasting. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms23031167","journal-title":"Int J Mol Sci"},{"key":"1093_CR135","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1515\/hsz-2017-0217","volume":"399","author":"J \u00c1brigo","year":"2018","unstructured":"\u00c1brigo J, Campos F, Simon F, Riedel C, Cabrera D, Vilos C, Cabello-Verrugio C (2018) TGF-\u03b2 requires the activation of canonical and non-canonical signalling pathways to induce skeletal muscle atrophy. Biol Chem 399:253\u2013264","journal-title":"Biol Chem"},{"key":"1093_CR136","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1016\/S0002-9440(10)63188-4","volume":"164","author":"Y Li","year":"2004","unstructured":"Li Y, Foster W, Deasy BM, Chan Y, Prisk V, Tang Y, Cummins J, Huard J (2004) Transforming growth factor-beta1 induces the differentiation of myogenic cells into fibrotic cells in injured skeletal muscle: a key event in muscle fibrogenesis. Am J Pathol 164:1007\u20131019","journal-title":"Am J Pathol"},{"key":"1093_CR137","doi-asserted-by":"publisher","first-page":"1262","DOI":"10.1038\/nm.3961","volume":"21","author":"DL Waning","year":"2015","unstructured":"Waning DL, Mohammad KS, Reiken S, Xie W, Andersson DC, John S, Chiechi A, Wright LE, Umanskaya A, Niewolna M, Trivedi T, Charkhzarrin S, Khatiwada P, Wronska A, Haynes A, Benassi MS, Witzmann FA, Zhen G, Wang X, Cao X, Roodman GD, Marks AR, Guise TA (2015) Excess TGF-\u03b2 mediates muscle weakness associated with bone metastases in mice. Nat Med 21:1262\u20131271","journal-title":"Nat Med"},{"key":"1093_CR138","doi-asserted-by":"publisher","first-page":"543","DOI":"10.3389\/fendo.2019.00543","volume":"10","author":"F Pin","year":"2019","unstructured":"Pin F, Bonetto A, Bonewald LF, Klein GL (2019) Molecular mechanisms responsible for the rescue effects of pamidronate on muscle atrophy in pediatric burn patients. Front Endocrinol (Lausanne) 10:543","journal-title":"Front Endocrinol (Lausanne)"},{"key":"1093_CR139","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.semcdb.2015.11.007","volume":"49","author":"JN Regan","year":"2016","unstructured":"Regan JN, Waning DL, Guise TA (2016) Skeletal muscle Ca(2+) mishandling: another effect of bone-to-muscle signaling. Semin Cell Dev Biol 49:24\u201329","journal-title":"Semin Cell Dev Biol"},{"key":"1093_CR140","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.bone.2015.05.023","volume":"80","author":"R Sartori","year":"2015","unstructured":"Sartori R, Sandri M (2015) BMPs and the muscle-bone connection. Bone 80:37\u201342","journal-title":"Bone"},{"key":"1093_CR141","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1038\/ng.2772","volume":"45","author":"R Sartori","year":"2013","unstructured":"Sartori R, Schirwis E, Blaauw B, Bortolanza S, Zhao J, Enzo E, Stantzou A, Mouisel E, Toniolo L, Ferry A, Stricker S, Goldberg AL, Dupont S, Piccolo S, Amthor H, Sandri M (2013) BMP signaling controls muscle mass. Nat Genet 45:1309\u20131318","journal-title":"Nat Genet"},{"key":"1093_CR142","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1126\/scitranslmed.aay9592","volume":"13","author":"R Sartori","year":"2021","unstructured":"Sartori R, Hagg A, Zampieri S, Armani A, Winbanks CE, Viana LR, Haidar M, Watt KI, Qian H, Pezzini C, Zanganeh P, Turner BJ, Larsson A, Zanchettin G, Pierobon ES, Moletta L, Valmasoni M, Ponzoni A, Attar S, Da Dalt G, Sperti C, Kustermann M, Thomson RE, Larsson L, Loveland KL, Costelli P, Megighian A, Merigliano S, Penna F, Gregorevic P, Sandri M (2021) Perturbed BMP signaling and denervation promote muscle wasting in cancer cachexia. Sci Transl Med 13:10","journal-title":"Sci Transl Med"},{"key":"1093_CR143","doi-asserted-by":"publisher","first-page":"1970","DOI":"10.3390\/cells9091970","volume":"9","author":"T Yoshida","year":"2020","unstructured":"Yoshida T, Delafontaine P (2020) Mechanisms of IGF-1-mediated regulation of skeletal muscle hypertrophy and atrophy. Cells 9:1970","journal-title":"Cells"},{"key":"1093_CR144","doi-asserted-by":"publisher","first-page":"4294","DOI":"10.1111\/febs.12253","volume":"280","author":"S Schiaffino","year":"2013","unstructured":"Schiaffino S, Dyar KA, Ciciliot S, Blaauw B, Sandri M (2013) Mechanisms regulating skeletal muscle growth and atrophy. Febs j 280:4294\u20134314","journal-title":"Febs j"},{"key":"1093_CR145","doi-asserted-by":"publisher","first-page":"2835","DOI":"10.1007\/s00421-020-04509-z","volume":"120","author":"BP Sullivan","year":"2020","unstructured":"Sullivan BP, Weiss JA, Nie Y, Garner RT, Drohan CJ, Kuang S, Stout J, Gavin TP (2020) Skeletal muscle IGF-1 is lower at rest and after resistance exercise in humans with obesity. Eur J Appl Physiol 120:2835\u20132846","journal-title":"Eur J Appl Physiol"},{"key":"1093_CR146","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1007\/s10522-013-9428-5","volume":"14","author":"L Bucci","year":"2013","unstructured":"Bucci L, Yani SL, Fabbri C, Bijlsma AY, Maier AB, Meskers CG, Narici MV, Jones DA, McPhee JS, Seppet E, Gapeyeva H, P\u00e4\u00e4suke M, Sipil\u00e4 S, Kovanen V, Stenroth L, Musar\u00f2 A, Hogrel JY, Barnouin Y, Butler-Browne G, Capri M, Franceschi C, Salvioli S (2013) Circulating levels of adipokines and IGF-1 are associated with skeletal muscle strength of young and old healthy subjects. Biogerontology 14:261\u2013272","journal-title":"Biogerontology"},{"key":"1093_CR147","doi-asserted-by":"publisher","DOI":"10.1242\/jeb.244650","author":"B Li","year":"2022","unstructured":"Li B, Feng L, Wu X, Cai M, Yu JJ, Tian Z (2022) Effects of different modes of exercise on skeletal muscle mass and function and IGF-1 signaling during early aging in mice. J Exp Biol. https:\/\/doi.org\/10.1242\/jeb.244650","journal-title":"J Exp Biol"},{"key":"1093_CR148","doi-asserted-by":"publisher","first-page":"e0115897","DOI":"10.1371\/journal.pone.0115897","volume":"10","author":"KH Lau","year":"2015","unstructured":"Lau KH, Baylink DJ, Sheng MH (2015) Osteocyte-derived insulin-like growth factor I is not essential for the bone repletion response in mice. PLoS ONE 10:e0115897","journal-title":"PLoS ONE"},{"key":"1093_CR149","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1038\/nature13528","volume":"513","author":"S Kir","year":"2014","unstructured":"Kir S, White JP, Kleiner S, Kazak L, Cohen P, Baracos VE, Spiegelman BM (2014) Tumour-derived PTH-related protein triggers adipose tissue browning and cancer cachexia. Nature 513:100\u2013104","journal-title":"Nature"},{"key":"1093_CR150","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/j.cmet.2015.11.003","volume":"23","author":"S Kir","year":"2016","unstructured":"Kir S, Komaba H, Garcia AP, Economopoulos KP, Liu W, Lanske B, Hodin RA, Spiegelman BM (2016) PTH\/PTHrP receptor mediates cachexia in models of kidney failure and cancer. Cell Metab 23:315\u2013323","journal-title":"Cell Metab"},{"key":"1093_CR151","doi-asserted-by":"publisher","first-page":"1582","DOI":"10.1002\/jcsm.12985","volume":"13","author":"BZC Weber","year":"2022","unstructured":"Weber BZC, Agca S, Domaniku A, Bilgic SN, Arabaci DH, Kir S (2022) Inhibition of epidermal growth factor receptor suppresses parathyroid hormone-related protein expression in tumours and ameliorates cancer-associated cachexia. J Cachexia Sarcopenia Muscle 13:1582\u20131594","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"1093_CR152","doi-asserted-by":"publisher","first-page":"6953421","DOI":"10.1155\/2020\/6953421","volume":"2020","author":"L Zhong","year":"2020","unstructured":"Zhong L, Yuan J, Huang L, Li S, Deng L (2020) RANKL is involved in Runx2-triggered hepatic infiltration of macrophages in mice with NAFLD induced by a high-fat diet. Biomed Res Int 2020:6953421","journal-title":"Biomed Res Int"},{"key":"1093_CR153","doi-asserted-by":"publisher","first-page":"E11238","DOI":"10.1073\/pnas.1707876115","volume":"114","author":"SP Kim","year":"2017","unstructured":"Kim SP, Frey JL, Li Z, Kushwaha P, Zoch ML, Tomlinson RE, Da H, Aja S, Noh HL, Kim JK, Hussain MA, Thorek DLJ, Wolfgang MJ, Riddle RC (2017) Sclerostin influences body composition by regulating catabolic and anabolic metabolism in adipocytes. Proc Natl Acad Sci U S A 114:E11238\u2013E11247","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1093_CR154","doi-asserted-by":"publisher","first-page":"4226","DOI":"10.1002\/jcp.30873","volume":"237","author":"H Oh","year":"2022","unstructured":"Oh H, Park SY, Cho W, Abd El-Aty AM, Hacimuftuoglu A, Kwon CH, Jeong JH, Jung TW (2022) Sclerostin aggravates insulin signaling in skeletal muscle and hepatic steatosis via upregulation of ER stress by mTOR-mediated inhibition of autophagy under hyperlipidemic conditions. J Cell Physiol 237:4226\u20134237","journal-title":"J Cell Physiol"},{"key":"1093_CR155","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1016\/j.bone.2011.04.017","volume":"50","author":"M Ferron","year":"2012","unstructured":"Ferron M, McKee MD, Levine RL, Ducy P, Karsenty G (2012) Intermittent injections of osteocalcin improve glucose metabolism and prevent type 2 diabetes in mice. Bone 50:568\u2013575","journal-title":"Bone"},{"key":"1093_CR156","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1210\/en.2012-2144","volume":"154","author":"B Zhou","year":"2013","unstructured":"Zhou B, Li H, Xu L, Zang W, Wu S, Sun H (2013) Osteocalcin reverses endoplasmic reticulum stress and improves impaired insulin sensitivity secondary to diet-induced obesity through nuclear factor-kappaB signaling pathway. Endocrinology 154:1055\u20131068","journal-title":"Endocrinology"},{"key":"1093_CR157","doi-asserted-by":"publisher","first-page":"584147","DOI":"10.3389\/fendo.2021.584147","volume":"12","author":"JS Wang","year":"2021","unstructured":"Wang JS, Mazur CM, Wein MN (2021) Sclerostin and osteocalcin: candidate bone-produced hormones. Front Endocrinol (Lausanne) 12:584147","journal-title":"Front Endocrinol (Lausanne)"},{"key":"1093_CR158","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.abb.2014.05.022","volume":"561","author":"M Ferron","year":"2014","unstructured":"Ferron M, Lacombe J (2014) Regulation of energy metabolism by the skeleton: osteocalcin and beyond. Arch Biochem Biophys 561:137\u2013146","journal-title":"Arch Biochem Biophys"},{"key":"1093_CR159","doi-asserted-by":"publisher","first-page":"9178616","DOI":"10.1155\/2021\/9178616","volume":"2021","author":"M Zhang","year":"2021","unstructured":"Zhang M, Nie X, Yuan Y, Wang Y, Ma X, Yin J, Bao Y (2021) Osteocalcin alleviates nonalcoholic fatty liver disease in mice through GPRC6A. Int J Endocrinol 2021:9178616","journal-title":"Int J Endocrinol"},{"key":"1093_CR160","doi-asserted-by":"publisher","first-page":"586","DOI":"10.7150\/ijbs.23256","volume":"14","author":"D Mattinzoli","year":"2018","unstructured":"Mattinzoli D, Ikehata M, Tsugawa K, Alfieri CM, Dongiovanni P, Trombetta E, Valenti L, Puliti A, Lazzari L, Messa P (2018) FGF23 and Fetuin-A interaction in the liver and in the circulation. Int J Biol Sci 14:586\u2013598","journal-title":"Int J Biol Sci"},{"key":"1093_CR161","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1016\/j.kint.2016.05.019","volume":"90","author":"S Singh","year":"2016","unstructured":"Singh S, Grabner A, Yanucil C, Schramm K, Czaya B, Krick S, Czaja MJ, Bartz R, Abraham R, Di Marco GS, Brand M, Wolf M, Faul C (2016) Fibroblast growth factor 23 directly targets hepatocytes to promote inflammation in chronic kidney disease. Kidney Int 90:985\u2013996","journal-title":"Kidney Int"},{"key":"1093_CR162","doi-asserted-by":"publisher","first-page":"1038638","DOI":"10.3389\/fmed.2022.1038638","volume":"9","author":"D Mattinzoli","year":"2022","unstructured":"Mattinzoli D, Li M, Castellano G, Ikehata M, Armelloni S, Elli FM, Molinari P, Tsugawa K, Alfieri CM, Messa P (2022) Fibroblast growth factor 23 level modulates the hepatocyte\u2019s alpha-2-HS-glycoprotein transcription through the inflammatory pathway TNFalpha\/NFkappaB. Front Med (Lausanne) 9:1038638","journal-title":"Front Med (Lausanne)"},{"key":"1093_CR163","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1007\/s00018-022-04319-w","volume":"79","author":"Y Cao","year":"2022","unstructured":"Cao Y, Mai W, Li R, Deng S, Li L, Zhou Y, Qin Q, Zhang Y, Zhou X, Han M, Liang P, Yan Y, Hao Y, Xie W, Yan J, Zhu L (2022) Macrophages evoke autophagy of hepatic stellate cells to promote liver fibrosis in NAFLD mice via the PGE2\/EP4 pathway. Cell Mol Life Sci 79:303","journal-title":"Cell Mol Life Sci"},{"key":"1093_CR164","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1016\/j.etp.2004.10.003","volume":"56","author":"AR Rincon-Sanchez","year":"2005","unstructured":"Rincon-Sanchez AR, Covarrubias A, Rivas-Estilla AM, Pedraza-Chaverri J, Cruz C, Islas-Carbajal MC, Panduro A, Estanes A, Armendariz-Borunda J (2005) PGE2 alleviates kidney and liver damage, decreases plasma renin activity and acute phase response in cirrhotic rats with acute liver damage. Exp Toxicol Pathol 56:291\u2013303","journal-title":"Exp Toxicol Pathol"},{"key":"1093_CR165","doi-asserted-by":"publisher","DOI":"10.1002\/hep.32671","author":"D Zhong","year":"2022","unstructured":"Zhong D, Cai J, Hu C, Chen J, Zhang R, Fan C, Li S, Zhang H, Xu Z, Jia Z, Guo D, Sun Y (2022) Inhibition of mPGES-2 ameliorates NASH by activating NR1D1 via heme. Hepatology. https:\/\/doi.org\/10.1002\/hep.32671","journal-title":"Hepatology"},{"key":"1093_CR166","doi-asserted-by":"publisher","first-page":"20656","DOI":"10.3390\/ijms151120656","volume":"15","author":"J Bi","year":"2014","unstructured":"Bi J, Ge S (2014) Potential roles of BMP9 in liver fibrosis. Int J Mol Sci 15:20656\u201320667","journal-title":"Int J Mol Sci"},{"key":"1093_CR167","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1007\/s13105-020-00763-z","volume":"76","author":"Y Wang","year":"2020","unstructured":"Wang Y, Ma C, Sun T, Ren L (2020) Potential roles of bone morphogenetic protein-9 in glucose and lipid homeostasis. J Physiol Biochem 76:503\u2013512","journal-title":"J Physiol Biochem"},{"key":"1093_CR168","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.bbrc.2022.07.018","volume":"623","author":"B Cui","year":"2022","unstructured":"Cui B, Yang L, Zhao Y, Lu X, Song M, Liu C, Yang C (2022) HOXA13 promotes liver regeneration through regulation of BMP-7. Biochem Biophys Res Commun 623:23\u201331","journal-title":"Biochem Biophys Res Commun"},{"key":"1093_CR169","doi-asserted-by":"publisher","first-page":"101482","DOI":"10.1016\/j.ghir.2022.101482","volume":"65","author":"SA Osganian","year":"2022","unstructured":"Osganian SA, Subudhi S, Masia R, Drescher HK, Bartsch LM, Chicote ML, Chung RT, Gee DW, Witkowski ER, Bredella MA, Lauer GM, Corey KE, Dichtel LE (2022) Expression of IGF-1 receptor and GH receptor in hepatic tissue of patients with nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. Growth Horm IGF Res 65:101482","journal-title":"Growth Horm IGF Res"},{"key":"1093_CR170","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1172\/JCI113451","volume":"81","author":"JF Caro","year":"1988","unstructured":"Caro JF, Poulos J, Ittoop O, Pories WJ, Flickinger EG, Sinha MK (1988) Insulin-like growth factor I binding in hepatocytes from human liver, human hepatoma, and normal, regenerating, and fetal rat liver. J Clin Invest 81:976\u2013981","journal-title":"J Clin Invest"},{"key":"1093_CR171","doi-asserted-by":"publisher","first-page":"3821","DOI":"10.3748\/wjg.v12.i24.3821","volume":"12","author":"JT Stefano","year":"2006","unstructured":"Stefano JT, Correa-Giannella ML, Ribeiro CM, Alves VA, Massarollo PC, Machado MC, Giannella-Neto D (2006) Increased hepatic expression of insulin-like growth factor-I receptor in chronic hepatitis C. World J Gastroenterol 12:3821\u20133828","journal-title":"World J Gastroenterol"},{"key":"1093_CR172","doi-asserted-by":"publisher","first-page":"1812","DOI":"10.1210\/clinem\/dgac088","volume":"107","author":"LE Dichtel","year":"2022","unstructured":"Dichtel LE, Cordoba-Chacon J, Kineman RD (2022) Growth hormone and insulin-like growth factor 1 regulation of nonalcoholic fatty liver disease. J Clin Endocrinol Metab 107:1812\u20131824","journal-title":"J Clin Endocrinol Metab"},{"key":"1093_CR173","doi-asserted-by":"publisher","first-page":"775","DOI":"10.21037\/atm-22-2742","volume":"10","author":"M Shi","year":"2022","unstructured":"Shi M, Zhou Z, Zhou Z, Shen L, Shen J, Zhou G, Zhu R (2022) Identification of key genes and infiltrating immune cells among acetaminophen-induced acute liver failure and HBV-associated acute liver failure. Ann Transl Med 10:775","journal-title":"Ann Transl Med"},{"key":"1093_CR174","doi-asserted-by":"publisher","first-page":"e76517","DOI":"10.1371\/journal.pone.0076517","volume":"8","author":"FF Liang","year":"2013","unstructured":"Liang FF, Liu CP, Li LX, Xue MM, Xie F, Guo Y, Bai L (2013) Activated effects of parathyroid hormone-related protein on human hepatic stellate cells. PLoS ONE 8:e76517","journal-title":"PLoS ONE"},{"key":"1093_CR175","doi-asserted-by":"publisher","first-page":"2665","DOI":"10.1210\/endo.138.7.5228","volume":"138","author":"JL Funk","year":"1997","unstructured":"Funk JL, Moser AH, Grunfeld C, Feingold KR (1997) Parathyroid hormone-related protein is induced in the adult liver during endotoxemia and stimulates the hepatic acute phase response. Endocrinology 138:2665\u20132673","journal-title":"Endocrinology"},{"key":"1093_CR176","first-page":"1037","volume":"41","author":"B Qin","year":"2021","unstructured":"Qin B, Diao N, Bai L (2021) Parathyroid hormone-related protein aggravates nonalcoholic fatty liver disease induced by methionine choline-deficient diet in mice. Nan Fang Yi Ke Da Xue Xue Bao 41:1037\u20131043","journal-title":"Nan Fang Yi Ke Da Xue Xue Bao"},{"key":"1093_CR177","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1507\/endocrj.EJ20-0728","volume":"69","author":"B Qin","year":"2022","unstructured":"Qin B, Qincao L, He S, Liao Y, Shi J, Xie F, Diao N, Bai L (2022) Parathyroid hormone-related protein prevents high-fat-diet-induced obesity, hepatic steatosis and insulin resistance in mice. Endocr J 69:55\u201365","journal-title":"Endocr J"}],"container-title":["Calcified Tissue International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00223-023-01093-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00223-023-01093-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00223-023-01093-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,6]],"date-time":"2023-07-06T17:04:05Z","timestamp":1688663045000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00223-023-01093-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,17]]},"references-count":177,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,7]]}},"alternative-id":["1093"],"URL":"https:\/\/doi.org\/10.1007\/s00223-023-01093-0","relation":{},"ISSN":["1432-0827"],"issn-type":[{"value":"1432-0827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,17]]},"assertion":[{"value":"6 March 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 May 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 May 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Anika Shimonty, Lynda F. Bonewald, Joshua R. Huot declare no potential conflicts of interest with respect to the research, authorship, and\/or publication of this article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict interest"}}]}}